Aquestive Therapeutics, Inc.
NASDAQAquestive Therapeutics enters the final week of June carrying two contradictory signals: the stock is up 7.6% over the past month — riding a 43.77% spike after the FDA waived an advisory committee meeting for its Anaphylm NDA — yet insiders have been steady sellers throughout the rally, and the ORTEX short score remains elevated near 78. The insider selling is the most notable…
Snapshot as of 28 Jun 2026
Aquestive Therapeutics enters the final week of June carrying two contradictory signals: the stock is up 7.6% over the past month — riding a 43.77% spike after the FDA waived an advisory committee meeting for its…
Aquestive Therapeutics reports Q1 results today with a notable insider selling cluster dominating the pre-earnings backdrop. The insider signal is the sharpest data point heading in. Five executives — including the…
Aquestive Therapeutics heads into its Q1 earnings release tomorrow with the entire C-suite having sold shares within the past week — a cluster of insider exits that frames everything else on the tape. The insider…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AQST — free to start on ORTEX.
Sign up for free →Open AQST on ORTEX